CMAJ • August 26, 2008; 179 (5). doi:10.1503/cmaj.071540.
© 2008 Canadian Medical Association or its licensors
All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association.
This Article
Right arrow Abstract
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Online Appendices
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Valiyeva, E.
Right arrow Articles by Anderson, G. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Valiyeva, E., PhD
Right arrow Articles by Anderson, G. M., MD PhD
Related Collections
Right arrow Drugs: psychiatry
Right arrow Adverse drug reactions
Right arrow Dementia
Right arrowRelated Articles

Effect of regulatory warnings on antipsychotic prescription rates among elderly patients with dementia: a population-based time-series analysis

Elmira Valiyeva, PhD, Nathan Herrmann, MD, Paula A. Rochon, MD MPH, Sudeep S. Gill, MD MSc and Geoffrey M. Anderson, MD PhD

From the Department of Health Policy, Management and Evaluation (Valiyeva, Rochon, Anderson), University of Toronto, Toronto, Ont.; the Institute for Clinical Evaluative Sciences (Valiyeva, Rochon, Gill, Anderson), Toronto, Ont.; the Division of Geriatric Psychiatry (Herrmann), Sunnybrook Health Sciences Centre, Toronto, Ont.; the Departments of Psychiatry (Herrmann) and Medicine (Rochon), University of Toronto, Toronto, Ont.; the Kunin-Lunenfeld Applied Research Unit, Baycrest (Rochon), Toronto, Ont.; and Providence Healthcare, Queen's University (Gill), Kingston, Ont


View this table:
[in this window]
[in a new window]

  		Table 1.

 

View this table:
[in this window]
[in a new window]

  		Table 2.

 

Figure 118
View larger version (30K):
[in this window]
[in a new window]

  		Figure 1: Estimated and predicted use of antipsychotic drugs overall before and after 3 warnings of serious adverse events associated with atypical antipsychotic drugs in elderly patients with dementia. Estimated rates, and predicted rates without warnings, represent estimates from our interrupted time-series analysis. The dashed blue lines represent 95% confidence intervals around the predicted estimates.

 

Figure 218
View larger version (31K):
[in this window]
[in a new window]

  		Figure 2: Estimated and predicted use of atypical antipsychotic drugs before and after 3 warnings of serious adverse events associated with atypical antipsychotic drugs in elderly patients with dementia. Estimated rates, and predicted rates without warnings, represent estimates from our interrupted time-series analysis. The dashed blue lines represent 95% confidence intervals around the predicted estimates.

 

Figure 318
View larger version (31K):
[in this window]
[in a new window]

  		Figure 3: Estimated and predicted use of conventional antipsychotic drugs before and after 3 warnings of serious adverse events associated with atypical antipsychotic drugs in elderly patients with dementia. Estimated rates, and predicted rates without warnings, represent estimates from our interrupted time-series analysis. The dashed blue lines represent 95% confidence intervals around the predicted estimates.

 

Figure 418
View larger version (29K):
[in this window]
[in a new window]

  		Figure 4: Estimated and predicted use of risperidone before and after 3 warnings of serious adverse events associated with atypical antipsychotic drugs in elderly patients with dementia. Estimated rates, and predicted rates without warnings, represent estimates from our interrupted time-series analysis. The dashed blue lines represent 95% confidence intervals around the predicted estimates.

 

Figure 518
View larger version (31K):
[in this window]
[in a new window]

  		Figure 5: Estimated and predicted use of olanzapine before and after 3 warnings of serious adverse events associated with atypical antipsychotic drugs in elderly patients with dementia. Estimated rates, and predicted rates without warnings, represent estimates from our interrupted time-series analysis. The dashed blue lines represent 95% confidence intervals around the predicted estimates.

 

Figure 618
View larger version (30K):
[in this window]
[in a new window]

  		Figure 6: Estimated and predicted use of quetiapine before and after 3 warnings of serious adverse events associated with atypical antipsychotic drugs in elderly patients with dementia. Estimated rates, and predicted rates without warnings, represent estimates from our interrupted time-series analysis. The dashed blue lines represent 95% confidence intervals around the predicted estimates.

 

View this table:
[in this window]
[in a new window]

  		Table 3.